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A B S T R A C T
Purpose: To describe a greater risk of fractures (about 2–6 times more often) in epilepsy children than in
children without epilepsy.
Methods: This article describe 126 epilepsy children in age 7–16 who were treated with Antiepileptic
Drugs (AEDs) in mono and add-on therapy during 5 years. In the control group were 132 children in age
7–16 without epilepsy and not treated with AEDs, observed in Outpatient Clinic due to headache for 5
years. In both groups we measured bone mineral density (BMD), the calcium and phosphate levels in
blood and urine and frequency of fractures. We analyzed both groups statistically (Mann–Whitney test).
Result: The frequency of fractures is 2–3 times greater in children with epilepsy then in the control
group. Osteoporosis and osteopenia is more often present in children who have taken AEDs.
Differences in calcium and phosphate levels in blood and urine between study and control group are
statistically signiﬁcant (p < 0.001).
Conclusion: Fractures are an important adverse effect in children who are taking AEDs.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Fractures in epilepsy are frequent in children and adults as was
described in literature.5,12,13,15 Risk of fractures in children after a
few years of taking AEDs is two to six times greater than in the
general population.5,12 Low BMD has been very often associated
with AEDs therapy.11
2. Methods
Wehave been observing 126 children in age 7–16with epilepsy
(80 boys and 46 girls) during 5 years (2003–2007). This study
group was treated with different antiepileptic drugs: valproid acid
(VPA), carbamazepine (CBZ), lamotrigine (LTG) and topiramate
(TPM) in mono and add-on therapy. Monotherapy was adminis-
tered to 59 patients (47%), add-on therapy to 67 patients. The
monotherapy group consist of: children on VPA: 16, children on
CBZ: 7, children on LTG: 26, children on TPM: 10. The add-on
therapy group consist of: children on VPA + CBZ: 19, children on
VPA + LTG: 32, children on VPA + TPM: 13, children on LTG + TPM:
3. Valproid acid was an element of therapy in 80 patients (63%): 16
patients onmonotherapy and 64 on add-on therapy. Children with
epilepsy were classiﬁed into two groups with different types of
epilepsy using the Terminology of International League Against* Tel.: +48 604091678; fax: +48 413319589.
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1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.04.013Epilepsy System from 19897: generalized epilepsy in 99 children
and localization-related epilepsy in 27 children.
The control group consisted of 132 healthy children in age 7–16
(87 boys and 45 girls).
Both in study and control group was measured bone mineral
density and z-score using dual energy X-ray (DEXA) technology
(DTX-200-V 1.63, Meditechnet). The measurement was taken in
the areas of lumbar spine and proximal femur. We have also
assessed the calcium and phosphate levels in blood and urine in
both groups.
All children has been on normal or rich in calcium and
phosphate diet. All patients had normal physical activity. All group
were statistically analyzed using Mann–Whitney U-test.
All patients gave written informed consent and the local Ethic
Committee had approved the study.
3. Results
The 126 patients and 132 controls had different scores of
bone mineral density (0.901  0.251 and 0.983 respectively)
(p < 0.00156). BMD was signiﬁcantly lower in study group compared
to controls.
Mean in study group in blood calcium level was 9.06  0.36
(mg/dL)whilst in the control group it was 9.32  0.33 (p < 0.000001).
Blood phosphate level mean in study group was 3.45  0.26 (mg/dL)
and in controls 4.14  0.3 (p < 0.000001). The calcium and phosphate
levels in blood were signiﬁcantly lower in epilepsy children group. In
urine mean of calcium level in study group was 130  22 (mg/24 h)
and in control group 147  28 (p < 0.000001) which means it wasvier Ltd. All rights reserved.
A. Gniatkowska-Nowakowska / Seizure 19 (2010) 324–325 325signiﬁcantly lower in study group. The mean of phosphate level in
urine were in epilepsy children 3.41  0.78 (g/24 h) and in controls
1.76  0.62 (p < 0.000001). These ﬁndings demonstrates that phos-
phate levels in urine were signiﬁcantly higher in epilepsy children
who treated with AEDs during 5 years.
The means of bone mineral density (BMD, g/cm2) in epilepsy
children were signiﬁcantly lower then in controls (0.901  0.251
and 0.983  0.121) (p < 0.00156).
In study group osteoporosis (z-score < 2.5) was observed in 9
children and osteopenia (z-score between1 and2.5) was found
in 29 children in comparison with control group where no child
suffered from osteoporosis and osteopeniawas found in 8 children.
In epilepsy group 43 patients had fractures while in control
group only 19 children had fractures (34% in study group
comparison of 14% in control group). This means the fractures
are 2.26 times more frequent in study group. The fractures in both
groupswere single and simple, limited to bones of lower and upper
extremities. The majority of those were the green-stick fractures.
In epilepsy group 10 patients on monotherapy had fractures
and from the add-on therapy group it was 33 patients. In both
groups (monotherapy and add-on therapy group) of patients who
had fractures, valproid acid is frequently used (35 patients on VPA
in a group of 43 patients with fractures, which means 81% of
patients on VPA in the group of patientswith fractures). The type of
therapy (especially therapy with VPA and add-on therapy) had
high inﬂuence in all scores in my study. The majority of children
was taking valproid acid due to generalized and secondary
generalized epilepsy and this medicine had high impact on
BMD, as well as calcium levels and phosphate levels in blood and
urine.
4. Discussion
Many authors discuss about patients treated with AEDs and
have analyzed an impact AEDs (especially VPA, CBZ and the add-on
therapy) have on bone mineral density and fractures in chil-
dren.1,2,3,8,12,13,15 It is very possible that lower BMD score is a result
of lower calcium and phosphate levels in blood and lower calcium
and higher phosphate level in urine in epilepsy children.2,5,9–14 The
epilepsy children with generalized and secondary generalized
epilepsy very often take VPA as the ﬁrst-line therapy in
monotherapy and add on-therapy. Valproid acid was told to have
a big inﬂuence in calcium and phosphate levels and in bony
mineral density according to many authors.1,3,4,6,8,14 After 5 years
of observation of children treated with AEDs we came to
conclusion that the greater number of fractures was a result of
lower bonemineral density in childrenwith epilepsy.5,12,13We feel
it very important to state that a diet rich with vitamin D and
calcium and phosphate improves the bone function.5. Conclusions
Fractures are more frequent in children with epilepsy,
especially in those who are treated with VPA and are on the
add-on therapy.
Children with epilepsy treated with AEDs have a signiﬁcantly
lower z-score, lower calcium levels in blood and urine, lower
phosphate level in blood and higher phosphate level in urine in
comparison with control group.
Differences are statistically signiﬁcant (p < 0.01).
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